2021
Living Donor Nephrectomy: Approaches, Innovations, and Outcomes
Merola J, Cooper M, Kulkarni S. Living Donor Nephrectomy: Approaches, Innovations, and Outcomes. 2021, 291-302. DOI: 10.1007/978-3-030-53618-3_13.Peer-Reviewed Original ResearchDonor nephrectomySuperior long-term outcomesLong-term outcomesCareful preoperative planningSingle-port surgeryKidney transplantationSurgical riskDeceased donorsOrgan recipientsSurgical approachSurgical considerationsSurgical techniqueKidney donationNephrectomyPreoperative planningInformed consentOutcomesAdequate trainingRiskDonorsAllograftsDonationSurgeryTransplantationSurgeons
2019
Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials
Schröppel B, Akalin E, Baweja M, Bloom RD, Florman S, Goldstein M, Haydel B, Hricik DE, Kulkarni S, Levine M, Mehrotra A, Patel A, Poggio ED, Ratner L, Shapiro R, Heeger PS. Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials. American Journal Of Transplantation 2019, 20: 564-572. PMID: 31452319, DOI: 10.1111/ajt.15580.Peer-Reviewed Original ResearchConceptsDeceased donor kidney transplant recipientsDonor kidney transplant recipientsKidney transplant recipientsGraft functionTransplant recipientsDeceased donor kidney transplantationDeceased donor kidney transplantAnti-C5 monoclonal antibodyDeceased donor recipientsRabbit antithymocyte globulinRate of DGFSerum creatinine reductionAdverse event incidenceDelayed graft functionDonor kidney transplantationDonor kidney transplantsIschemia-reperfusion injuryHigh-risk populationSafety/efficacyObservational human dataAntithymocyte globulinDGF rateKidney transplantationDonor recipientsKidney transplant
2017
A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney Transplantation
Kulkarni S, Do A, Liapakis A. A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney Transplantation. Internal Medicine Review 2017, 3 DOI: 10.18103/imr.v3i9.570.Peer-Reviewed Original Research
2016
Parathyroidectomy prior to kidney transplant decreases graft failure
Callender GG, Malinowski J, Javid M, Zhang Y, Huang H, Quinn CE, Carling T, Tomlin R, Smith JD, Kulkarni S. Parathyroidectomy prior to kidney transplant decreases graft failure. Surgery 2016, 161: 44-50. PMID: 27863776, DOI: 10.1016/j.surg.2016.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesConfidence IntervalsDatabases, FactualFemaleGraft RejectionGraft SurvivalHumansHyperparathyroidismKidney Failure, ChronicKidney TransplantationMaleMiddle AgedOdds RatioParathyroid HormoneParathyroidectomyPreoperative CareRetrospective StudiesRisk AssessmentTreatment OutcomeConceptsYear post-kidney transplantationPost-kidney transplantationDelayed graft functionGraft failureKidney transplantationGraft functionParathyroid hormoneUremic hyperparathyroidismKidney diseaseFirst year post-kidney transplantationSerum parathyroid hormone levelsCurrent Kidney DiseaseGlobal Outcomes (KDIGO) guidelinesParathyroid hormone levelsSerum parathyroid hormoneAdult patientsKidney transplantOutcomes guidelinesRetrospective reviewSingle institutionCurrent guidelinesHormone levelsSurvival 1ParathyroidectomyTransplantationBelatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report
Merola J, Yoo PS, Schaub J, Smith JD, Rodriguez-Davalos MI, Tichy E, Mulligan DC, Asch W, Formica R, Kashgarian M, Kulkarni S. Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report. Transplantation Proceedings 2016, 48: 3106-3108. PMID: 27932157, DOI: 10.1016/j.transproceed.2016.04.005.Peer-Reviewed Original ResearchConceptsCalcineurin inhibitorsHemolytic uremic syndromeThrombotic microangiopathyKidney transplantationUremic syndromeMinimization of CNIsAtypical hemolytic uremic syndromeWithdrawal of tacrolimusEarly graft lossFavorable clinical courseGraft dysfunctionGraft lossImmunosuppression strategiesUsual therapyClinical courseCase reportCTLA-4Endothelial reactionFrequent causeChallenging causeUncontrolled activationMonoclonal antibodiesCellular destructionMicroangiopathyComponent C5
2015
Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial
Rostaing L, Bunnapradist S, Grinyó J, Ciechanowski K, Denny J, Silva H, Budde K, Group E, Denny J, Kulkarni S, Hricik D, Bresnahan B, Bunnapradist S, El-Sabrout R, Chan L, Ciancio G, El-Ghoroury M, Goldstein M, Gaston R, Gohh R, Killackey M, King A, Knight R, Kore A, Sudan D, Friedmann J, Mulgaonkar S, Nolan C, Pankewycz O, Pirsch J, Schaefer H, Steinberg S, Gelb B, True K, West-Thielke P, Waybill M, Wolf J, Ketel B, Harland R, Shihab F, Cassuto E, Le Meur Y, Rostaing L, Mariat C, Grinyó J, Puig J, Seron D, Tisone G, Ciechanowski K, Foroncewicz B, Wlodarczyk Z, Budde K, Witzke O, Mondragon G, Urrea E, Gomez J, Acevedo R, del Carmen Rial M, Novoa P, Silva H, Garcia V, Carvalho D, Saber L, Contieri F, Bastos M, Manfro R, Kanellis J, Eris J, O’Connell P, Hughes P, Russ G, Pidgeon G, Dittmer I, Kee T, Vathsala A, Naumovic R, Mitic I, Parmjeet R. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. American Journal Of Kidney Diseases 2015, 67: 648-659. PMID: 26717860, DOI: 10.1053/j.ajkd.2015.10.024.Peer-Reviewed Original ResearchConceptsTotal daily doseDe novo kidney transplant recipientsNovo kidney transplant recipientsKidney transplant recipientsIR-TacKidney transplantationTransplant recipientsAdverse eventsTreatment failureDaily extended-release tacrolimusDe novo kidney transplantationMean total daily doseLower total daily doseExtended-release tacrolimusOnce-Daily ExtendedTarget trough rangesTwice-Daily TacrolimusNew-onset diabetesSafety end pointSerious adverse eventsPhase 3 trialImmediate-release tacrolimusParticipant eligibility criteriaTwo-year resultsImproved bioavailability
2014
Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment.
Kulkarni S, Nancy K, Formica R, Moeckel G, Pober J. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment. Transplantation 2014, 98: 79. DOI: 10.1097/00007890-201407151-00247.Peer-Reviewed Original ResearchAntibody-Mediated InjuryEculizumab therapyKidney transplantationInterim assessmentTransplantationInjuryTherapy
2011
Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience
Cimsit B, Schilsky M, Moini M, Cartiera K, Arvelakis A, Kulkarni S, Formica R, Caldwell C, Taddei T, Asch W, Emre S. Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience. Transplantation Proceedings 2011, 43: 901-904. PMID: 21486624, DOI: 10.1016/j.transproceed.2011.02.033.Peer-Reviewed Original ResearchConceptsLiver-kidney transplantationHigh MELD scoreKidney transplantationMELD scoreKidney diseaseEnd-stage liver disease (MELD) scoreCombined liver-kidney transplantationGraft/patient survivalLow glomerular filtration rateOrgan allocation algorithmsPrimary biliary sclerosisRecurrence of HCVSevere HCV recurrenceTransplantation of patientsLiver Disease scoreSerum creatinine levelsRenal allograft rejectionSingle-center experienceGlomerular filtration rateHepatitis C virusPolycystic kidney diseaseBiliary sclerosisHCV recurrenceIschemic hepatitisOLT patients
2010
Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information?
Formica RN, Asch WS, Wagner KR, Kulkarni S. Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information? Clinical Journal Of The American Society Of Nephrology 2010, 5: 924-928. PMID: 20203162, PMCID: PMC2863980, DOI: 10.2215/cjn.06820909.Peer-Reviewed Original ResearchConceptsHIV-positive individualsKidney transplantationMedical historyRecipient's medical historyAlternative treatment optionHIV statusKidney donorsTreatment optionsKidney donationConsensus groupTransplantationDonation procedureAbstractTextRecipient's rightRecipientsPotential donorsHealth informationPotential recipientsSpecific diseasesPanel reviewHIVDonors' rightsRiskDonorsState statues